Medline (MDLN)
Integrates medical-surgical products, third-party distribution, logistics, and clinical implementation support.
Something off on this page? Send us feedback.
Combines Medline Brand products in Front Line Care, Surgical Solutions, and Laboratory and Diagnostics with Supply Chain Solutions for third-party distribution and logistics. Sales are split roughly evenly between the two segments, while branded products contribute most segment earnings; global sourcing, delivery continuity, product quality, and Prime Vendor relationships shape the model.
Combines owned medical-surgical products with a broad third-party catalog through two segments: Medline Brand and Supply Chain Solutions. Front Line Care, Surgical Solutions, and Laboratory and Diagnostics span consumables, devices, and clinical product systems.
Serves hospitals and non-acute care sites through Prime Vendor contracts, distribution centers, an owned U.S. fleet, and clinical implementation support. Global manufacturing and sourcing feed a business whose sales are split roughly evenly between branded products and supply-chain services, while branded products contribute most segment earnings.
Execution rests on keeping products available, coordinating a wide supplier base, and delivering reliably across the network. Product quality and regulatory compliance, supplier and technology continuity, multi-year customer relationships, and principal-stockholder influence over board nominations shape the structure.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 27, 2026 | BTIG | Reiterate | Rating: —Target: $50 | Target: $55 |
| Aug 6, 2026 | Robert W. Baird | Target | Target: $45 | Target: $42 |
| Aug 6, 2026 | Evercore ISI | Target | Target: $55 | Target: $39 |
| Aug 6, 2026 | Stifel Nicolaus | Target | Target: $55 | Target: $45 |
| Aug 6, 2026 | BMO Capital | Reiterate | Rating: —Target: $45 | Target: $47 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.68B · Total debt $12.64B · Total assets $39.35B · Shareholders' equity $11.57B
- Revenue
- $7.69B
- Operating income
- $395.0M
- Net income
- $60.0M
No dividends on record.
| Institutions | ≈ 88.49% | 748.30M shares | |
|---|---|---|---|
| 422 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Strategic holders | 41.13% | 347.78M shares | |
| 2 holders · as of Jun 1, 2026 | |||
| Adds to | 129.62% | ||
845.61M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 129.62%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BCP 8 Holdings Mozart Manager L.L.C.Strategic10 percent owner | 24.23% | 101.79M · 51.54M · 51.54M | filed Jun 1, 2026 |
Carlyle Group Inc.Institution | 22.12% | 187.08M | as of Jun 30, 2026 |
Mozart Aggregator II LP1Strategic10 percent owner | 16.90% | 142.92M | filed Dec 22, 2025 |
H&F Corporate Investors X, Ltd.Institution | 8.38% | 70.87M | as of Jun 30, 2026 |
FMR LLCInstitution | 5.55% | 46.96M | as of Jun 30, 2026 |
- Mozart Aggregator II LP reports a block also reported by H&F Corporate Investors X, Ltd.; it is counted once, under H&F Corporate Investors X, Ltd.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 28, 2026 | BCP 8 Holdings Mozart Manager L.L.C. | 10 percent owner | −33,317,824 | $36.54 |
| Mar 10, 2026 | BCP 8 Holdings Mozart Manager L.L.C. | 10 percent owner | −27,852,986 | $40.51 |
| Mar 10, 2026 | Carlyle Group Inc. | 10 percent owner | −26,105,840 | $41.00 |
| Dec 18, 2025 | Mozart Aggregator II LP | 10 percent owner | −20,417,040 | $28.37 |
| Dec 18, 2025 | Carlyle Group Inc. | 10 percent owner | −19,136,333 | $29.00 |
- Cardinal Health
Integrated rival in med-surg distribution and branded supplies
- McKesson
National rival in med-surg distribution and non-acute logistics
- BD
Broad manufacturer rival in vascular access, diagnostics, and surgery
- Henry Schein
Office-based distributor with national and corporate-brand breadth
- Solventum
Product rival in wound care, infection prevention, and surgical support
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Medline | $33.73 | +5.54% | $27.03B | 37.2 | 22.8 | 0.9 | — |
| Cardinal Health | $227.41 | +0.74% | $52.87B | 31.2 | 18.2 | 0.2 | +5.8% |
| McKesson | $894.89 | +0.95% | $103.79B | 23.7 | 19.3 | 0.3 | +7.7% |
| BD | $182.06 | +0.75% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Henry Schein | $87.19 | +2.33% | $9.71B | 24.8 | 15.4 | 0.7 | +6.7% |
| Solventum | $89.19 | +0.39% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| Median | 24.8 | 15.4 | 0.7 | +5.8% |